At ImmunOs Therapeutics AG, we have discovered a novel family class of therapeutics to explore ways to stimulate the innate immune system and increase the efficacy of checkpoint inhibitors (CTLA-4, PD-1, PD-L1) and costimulatory agonists (e.g. 4-1BB) in multiple cancers (e.g. Pancreatic, Colon, Melanoma, Lymphoma, and Breast). Our products differentiate from the common competitor antibodies, as we not only target a single receptor (as antibodies do) but target diverse receptors using one molecule to create a synergistic response between immune cells that activate anti-tumor responses. We also explore the combination of our products with diverse types of cancer therapies, such as chemotherapy, vaccines, etc.
The immune system’s natural capacity to detect and destroy abnormal cells may prevent the development of many cancers. However, cancer cells are sometimes able to avoid detection and destruction by the immune system through different mechanisms such as reduction of the expression of tumor antigens on their surface; expression of proteins on their surface that induces immune cell activation; or by inducing cells in the surrounding environment.
Immunomodulators are substances that are capable of stimulating the immune system by inducing or reducing the activity of any of its components to recognize and destroy cancer cells. Current challenges within immunomodulators relate to the variable response rates in cancer patients, lack of defined biomarkers to assess the response to therapy, and the medical need for treatment of diverse cancer indications. So far, immunomodulatory checkpoint antibodies have been approved for advanced melanoma, metastatic non-small lung cell cancer, metastatic renal carcinoma, and others, but there is still a big gap of potential cancer indications where novel therapeutics can be explored and response rates remain low.
The use of combinatorial approaches using immunomodulators and personalized treatments may tackle some of the current challenges in cancer therapy. Combinatorial approaches in cancer are highly attractive for exploration since not all cancer patients benefit from treatment with a single agent. This has led to improved results for diverse cancer indications in clinical trials. A number of drug combinations that include checkpoint antibodies inhibitors are being evaluated and a dual immune-checkpoint blockade was approved for melanoma (CTLA4 + PD-1). At ImmunOs Therapeutics AG, our novel family class of immunomodulators that stimulate the immune system and increase the efficacy of checkpoint inhibitors ( CTLA-4, PD-1, PD-L1) and costimulatory agonists (e.g. 4-1BB) in combinatorial therapies is the next wave of personalized treatments to support patients with a diverse set of cancer indications.